文献速递精神分裂症与精神病性障碍

新型甘氨酸转运体抑制剂BI 425809治疗精神分裂症认知障碍的2期研究

Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study.
PubMed 文献 · Lancet Psychiatry · 2021-01-01

这项2期随机双盲安慰剂对照试验在509例精神分裂症门诊患者中评估了BI 425809每日口服添加治疗12周对认知的影响。五种剂量反应模型显示BI 425809优于安慰剂,10 mg和25 mg组MCCB总体复合T评分改善显著大于安慰剂,不良事件组间均衡。

要点

  • BI 425809 10 mg和25 mg组第12周MCCB总体复合T评分较基线改善显著优于安慰剂。
  • 六种预设剂量反应模型中五种显示BI 425809对安慰剂有统计学显著获益。
  • 不良事件各组间均衡,10 mg和25 mg组发生率分别为41%和42%,安慰剂组44%。

核心结论

  • BI 425809每日口服添加治疗12周可改善精神分裂症患者的认知,10 mg和25 mg剂量与安慰剂分离最大。
  • 若3期试验证实这些结果,BI 425809可能成为精神分裂症相关认知障碍的有效治疗。

研究设计与样本

  • 2期随机双盲安慰剂对照平行组试验,在11个国家81个中心进行。
  • 纳入18-50岁接受稳定治疗的精神分裂症门诊患者,随机分配至BI 425809 2 mg、5 mg、10 mg、25 mg或安慰剂(1:1:1:1:2)添加治疗12周。
  • 共509例患者随机分配(2 mg组85例、5 mg组84例、10 mg组85例、25 mg组85例、安慰剂组170例),444例(87%)完成12周治疗。
  • 主要终点为第12周MATRICS共识认知成套测验(MCCB)总体复合T评分较基线的变化。
  • 采用多重比较程序与建模方法及混合模型重复测量评估六种预设剂量反应模型。

主要发现

  • 不良事件各组间均衡:2 mg组50例(59%)/85例,5 mg组44例(52%)/84例,10 mg组35例(41%)/85例,25 mg组36例(42%)/85例,安慰剂组74例(44%)/170例。

关键数值与推荐

  • 主要终点为第12周MCCB总体复合T评分较基线的变化。
  • 六种预设剂量反应模型采用多重比较程序与建模方法评估,五种模型显示统计学显著获益。

临床怎么用

  • 目前尚无获批药物治疗精神分裂症相关认知障碍,BI 425809的2期结果提示10 mg和25 mg每日口服添加可能改善认知。
  • 需等待3期试验验证后方可考虑临床应用。

局限性

  • 为2期试验,样本量有限,结果需3期试验确认。
  • 疗效分析仅纳入有基线数据和至少一次基线后治疗中测量数据的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cognitive impairment associated with schizophrenia predicts poor functional outcomes, but currently no approved pharmacotherapy is available. This study investigated whether the glycine transporter-1 inhibitor BI 425809 improves cognition in patients with schizophrenia. METHODS: This phase 2, randomised, double-blind, placebo-controlled, parallel-group trial (81 centres, 11 countries), randomly assigned outpatients (aged 18-50 years) with schizophrenia on stable treatment to add-on once-daily oral BI 425809 2 mg, 5 mg, 10 mg, or 25 mg or placebo (1:1:1:1:2) for 12 weeks. Treatment was assigned in blocks using interactive response technology; patients, investigators, and all trial personnel were masked to group assignment. The primary endpoint was change from baseline in MATRICS Consensus Cognitive Battery (MCCB) overall composite T-score at week 12. Six predefined dose-response models were evaluated using a multiple comparison procedure and modelling approach with mixed model repeated measures to assess evidence for a non-flat dose-response relationship for cognitive improvements with BI 425809. Adverse events were monitored. Safety analyses included all randomly allocated patients who received one or more doses of trial medication; efficacy analyses included patients from this set who also had available baseline data and at least one post-baseline on-treatment measurement for the primary or secondary endpoint. This study is registered with ClinicalTrials.gov, number NCT02832037. FINDINGS: 509 patients were randomly assigned between April 25, 2018, and Oct 4, 2019 (BI 425809 2 mg, n=85; 5 mg, n=84; 10 mg, n=85; 25 mg, n=85; placebo, n=170 444 (87%) completed the 12-week treatment. Five of six dose-response models showed a statistically significant benefit of BI 425809 over placebo (linear [t=2·55, p=0·015], linear in log [t=2·56, p=0·015]; Emax [t=2·75, p=0·0089], sigmoid Emax [t=2·98, p=0·0038], logistic [t=2·77, p=0·0085]). Pairwise comparisons showed greater mean improvement from baseline in MCCB overall composite T-score at week 12 with BI 425809 10 mg and 25 mg versus placebo (adjusted mean difference 1·98 [95% CI 0·43-3·53] for 10 mg and 1·73 [0·18-3·28] for 25 mg; standardised effect size 0·34 for 10 mg and 0·30 for 25 mg). Adverse events were balanced across groups, reported in 50 (59%) of 85 patients on BI 425809 2 mg, 44 (52%) of 84 on 5 mg, 35 (41%) of 85 on 10 mg, 36 (42%) of 85 on 25 mg, and 74 (44%) of 170 on placebo. INTERPRETATION: BI 425809 improved cognition after 12 weeks in patients with schizophrenia; doses of 10 mg and 25 mg showed the largest separation from placebo. If these encouraging results are confirmed in phase 3 trials, BI 425809 could provide an effective treatment for cognitive impairment associated with schizophrenia. FUNDING: Boehringer Ingelheim.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Fleischhacker WW, Podhorna J, Gröschl M, et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021. PMID: 33610228. doi:10.1016/S2215-0366(20)30513-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。